Diabetes — the whole-body one

Diabetes is treated as a number, but it is a whole-body disease — and a silent one.

It reaches everywhere the blood goes: the kidneys, the eyes, the nerves, the heart and vessels, the gut. Often there is no symptom until the damage is advanced. The real danger is rarely the sugar reading itself. It is the damage building in the organs no one happens to be watching, while everyone watches the number.

This chapter is still a draft — we are still writing it, and your thoughts and comments are very welcome while we do.

Who connects it: your PCP holds the whole picture; endocrine and the organ specialists each own a part. Bring the reach list above to your PCP and ask who is watching each one.

Go deeper

4 layers below. Open any one.

A single HbA1c or glucose reading tells you how sweet the blood is today. HbA1c stands for glycated haemoglobin. The reading does not tell you what the years of it have done to the small vessels feeding each organ. Two people with the same number can be in very different trouble.

That is why the organ checks matter more than any one reading: kidney, eye, nerve, foot, vascular. And it is why they belong on a fixed calendar, rather than waiting for a symptom.

Once diabetes is on the chart, new damage is easy to blame on it, and to stop looking. But the organs usually travel together. Heavy protein in the urine with healthy eyes is a mismatch. Diabetic kidney disease and diabetic eye disease normally arrive as a pair. So protein without retinopathy is a flag that another driver may be at work.

See MGRS, monoclonal gammopathy of renal significance, and C3G, C3 glomerulopathy. Both get missed when the diabetes is assumed to be enough. Blaming it ends the search too early.

The biggest change in diabetes care is that the goal moved from the glucose number to protecting the organs. Two drug classes drive it: SGLT2 inhibitors and GLP-1 agonists. SGLT2 stands for sodium-glucose cotransporter 2. GLP-1 stands for glucagon-like peptide-1.

Both protect the kidney and the heart beyond their effect on sugar. Strong evidence That is why guidelines now add them for organ protection, not glucose alone. Guidelines increasingly treat them as complementary “cardio-kidney-metabolic” pillars, rather than a choice of either one or the other. Blood-pressure and protein control protect the kidney as much as sugar does.

Worth asking about: say you have type 2 diabetes, and you are not on an SGLT2 inhibitor or a GLP-1 agonist. If no reason you can’t be has been explained, that is a fair question to raise. Current evidence favours them for most.

And the most useful habit stays the boring one: the scheduled organ checks, kept the same way each time. That way, a change is a real trend, not noise. This is one connected system. See the gut–heart connection.

A fast-moving research front ties diabetes to the gut. GLP-1, short for glucagon-like peptide-1, is the hormone the new drugs imitate. It is made by cells in the gut, in response to what the microbes there produce. Those are short-chain fatty acids, such as butyrate.

In animals, an SGLT2 inhibitor reshaped the gut microbiome in a way that raised GLP-1. SGLT2 stands for sodium-glucose cotransporter 2. The change appeared to regenerate insulin-making beta cells. The benefit transferred with a faecal transplant, and disappeared when GLP-1 was blocked. That points to a real causal pathway. Early evidence

The same gut route may feed kidney damage, with a leaky gut and dysbiosis generating toxins that stress the kidney. This is early, largely animal or small human work. But it is why the gut as one system keeps turning up next to diabetes. A direction to watch, not a treatment plan.

Questions to bring

Copy these, or read them out. They fit in a short visit.

Beyond my HbA1c, or glycated haemoglobin, is each of these being checked on a schedule? My kidneys, through urine protein. My eyes, nerves and feet. My vascular risk.
My urine shows protein but my eyes are fine — should we look past the diabetes for the cause?

The short version

Getting ahead of it: Treat the organs, not just the number — get the kidney, eye, nerve, foot and vascular checks on a schedule from the start, not after something breaks.
Your testing regime: HbA1c AND a urine albumin-to-creatinine ratio, eGFR (creatinine + cystatin C), a dilated eye exam, a foot and nerve check, and lipids — on a fixed calendar.
What they don’t tell you: Good control lowers the risk but never zeroes it, and the damage is usually silent until advanced — so the scheduled checks matter more than how you feel.
What it can spawn: Kidney disease, sight loss, neuropathy and foot ulcers, heart attack and stroke, and gut and autonomic problems — the whole downstream web.
What it’s confused with: Its own damage — protein-losing kidney disease with healthy eyes can be MGRS or C3G, not the diabetes; blaming it ends the search too early.

From general clinical literature and the project’s diabetes research; the grades mark how strong the evidence is. Not a diagnosis; nothing here comes from any individual’s medical record.

Also asked as: what high blood sugar is quietly doing elsewhere · “how to lower blood sugar without drugs” · “prediabetes what now” · “does diabetes hurt my kidneys” (diabetes and blood sugar)